What's new? Log in Free sign up

Filing search / Mirum Pharmaceuticals, Inc. / "Reimbursement"

Search information

Mirum Pharmaceuticals, Inc.

Companies

"Reimbursement"

Keywords

SEC filings

Source

Export list of results

Export a CSV file of filings or unique companies (up to first 5,000 results).

Download list of filings Download list of companies

88 results

Newest first Best match first

MIRM Mirum Pharmaceuticals, Inc.

approved medicines and our product candidates, as well as third-party payor coverage and reimbursement for our approved medicines and our product … such as managed care organizations, group-purchasing organizations, specialty pharmacies, government accounts and reimbursement support. Based on the number

26 Feb 25

4:09pm

MIRM Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update

Medicines net product sales totaled $123.1 million. Global LIVMARLI business grew to 30 countries with commercial access, including successful reimbursement

MIRM Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals Announces Preliminary Unaudited 2024 Net Product Sales and Cash Balance and Provides Corporate Updates

, including successful reimbursement negotiation and launch in the four major European markets Regulatory and Pipeline: Expanding Mirum's leadership

MIRM Mirum Pharmaceuticals, Inc.

Quarterly report

distribution capabilities in these locations and others where our products are available; the availability of adequate reimbursement and a commercially viable … adequate coverage and reimbursement for our approved medicines and any future product candidates, if approved. The availability of coverage and adequate

12 Nov 24

8:14am

MIRM Mirum Pharmaceuticals, Inc.

Quarterly report

expense reimbursement from our collaboration partners and increased expenses associated with a label expansion study; for volixibat programs, an increase … reimbursement from our collaboration partners and increased expenses associated a label expansion study; for volixibat programs, an increase of $5.4

7 Aug 24

4:11pm

y49ebjsl54mrutjh

Quarterly report

8 May 24

4:16pm

crshzrji6b8trse3

15 Mar 24

5:03pm

9z88 j90lcs0zciwwh

15 Mar 24

5:03pm

kfo dp1oqkn8zlnzqic0

15 Mar 24

5:03pm

Mirum Pharmaceuticals Announces Preliminary Unaudited 2023 Net Revenue and Provides Corporate Updates

Prospectus supplement for primary offering

Quarterly report

2 Nov 23

4:15pm

Quarterly report

2 Nov 23

4:15pm

Financial Statements and Exhibits

Financial Statements and Exhibits

fl836reaqf0nwdesqw

Automatic shelf registration

wv8k405oq3gdu kvj

Departure of Directors or Certain Officers

o7pnylwaemw2grp0p2f6

Quarterly report

7 Aug 23

6:16am

uxno ysr2x9r3cv0

Mirum Pharmaceuticals Enters Agreement to Acquire Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases from Travere Therapeutics

Prev
1
2
3
4
5
Next

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.